AbbVie vs Gilead Sciences
AbbVie is the larger business, with $61.16bn of revenue in fiscal 2025 against $29.44bn for Gilead Sciences (2.1 times as much). AbbVie grew faster (8.6% against 2.4%). Gilead Sciences kept more of each dollar of sales as profit: a net margin of 28.9% against 6.9%.
| Latest fiscal year | AbbVieABBV, 2025 | Gilead SciencesGILD, 2025 |
|---|---|---|
| Revenue | $61.16bn | $29.44bn |
| Revenue growth | 8.6% | 2.4% |
| Net income | $4.23bn | $8.51bn |
| Operating margin | 24.6% | 34.0% |
| Net margin | 6.9% | 28.9% |
| Return on equity | — | 40.5% |
| Free cash flow | $17.82bn | $9.46bn |
| Cash | $5.23bn | $7.56bn |
| Total debt | $67.50bn | $24.94bn |
| Debt to equity | — | 109.8% |
| Dividend per share | $6.65 | $3.16 |
| Dividend yield | 2.4% | 1.9% |
| Share buybacks | $980m | $1.92bn |
| Employees | 57,000 | 17,000 |
| Market value | $505.48bn | $208.99bn |
| Price vs our value range | Within our value range | Within our value range |
| Moat score | 87 (Strong) | 79 (Strong) |
| Insider trades, 12 months | 0 buys, 6 sales | 0 buys, 83 sales |